Health and Healthcare
RNAi developments by Alnylam, CytRx Highlight Tuesday's Biotech News
Published:
by H.S. Ayoub
BioHealth Investor.com
The Nasdaq Biotechnology Index ( ^NBI) gained slightly on Tuesday ending the trading session at $807.34.
Alnylam Pharmaceuticals (ALNY) gained almost 9% on the day after the company announced it has taken a worlwide exclusive license to use Inex Pharmaceuticals’ (IEX.TO) liposomal delivery formulation technology for discovery and development of RNA Interference (RNAi) products. The deal also allows Inex to develop its own RNAi based products.
Not to be outdone, CytRx Corp (CYTR) jumped more than 15% as the company announced it had established a new subsidiary dedicated to RNAi technology research. RXi Pharmaceuticals will be lead by top notch scientists including Nobel Prize winner, for his work on RNAi research, Dr. Craig C. Mello.
Shares of AtheroGenics (AGIX) tumpled more than 10% following the company’s decision to delay the release of data from its phase III clinical trial results of AGI-1067 for the treatment of coronary artery disease. The company was slated to present the data at the J.P. Morgan Healthcare Conference on Wednesday afternoon, but instead it will make the presentation in March at the American College of Cardiology meeting.
http://www.biohealthinvestor.com/
Sponsored: Want to Retire Early? Start Here
Want retirement to come a few years earlier than you’d planned? Orare you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
